Gastroenterology · Proton Pump Inhibitor
The submission of a supplemental application for Omeprazole by Dr. Reddy's could significantly alter the competitive dynamics in the proton pump inhibitor market. Monitoring the FDA's review process is essential for understanding potential shifts in market share and regulatory compliance.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 8/1/2026, 12:31:41 AM
Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The submission of a supplemental application for Omeprazole by Dr. Reddy's could significantly alter the competitive dynamics in the proton pump inhibitor market. Monitoring the FDA's review process is essential for understanding potential shifts in market share and regulatory compliance. Regulatory context from FDA (FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (4 high-relevance).
Portfolio teams should monitor the review process and potential approval timelines to assess market strategy for Omeprazole. The strongest clinical anchor is A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Proton Pump Inhibitor, 5 regulatory and 3 competitive items passed relevance filtering for Dr.
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This submission may impact the competitive landscape for proton pump inhibitors, particularly if approved, as it could enhance Dr.
Regulatory risk is concentrated around FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL) (FDA). Entity match (omeprazole); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The unknown review priority indicates uncertainty in the approval timeline, which could affect strategic planning for companies involved in the proton pump inhibitor space.
FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)
FDAhigh relevance
Entity match (omeprazole); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)
FDAhigh relevance
Entity match (omeprazole); Regulatory pathway relevance (nda)
FDA document
View sourceFDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceInnovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceRegister to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceReal-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePhase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceU.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Lenalidomide ANDA217554 Submission by Deva Holding AS
Humanexa Signalsmedium relevance
Moderate corpus alignment
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceArtificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEfficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePreclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRecent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe submission of a supplemental application for Omeprazole by Dr. Reddy's could significantly alter the competitive dynamics in the proton pump inhibitor market. Monitoring the FDA's review process is essential for understanding potential shifts in market share and regulatory compliance.
If approved, Dr. Reddy's could gain a stronger foothold in the proton pump inhibitor market, potentially affecting the revenue and market share of existing competitors.
The unknown review priority indicates uncertainty in the approval timeline, which could affect strategic planning for companies involved in the proton pump inhibitor space.
Follow up on the review status and any updates regarding the approval timeline from the FDA.
Track for follow-up milestones; no immediate action required.